Lares-Asseff I, Trujillo-Jiménez F
Unidad de Farmacología Clínica, Instituto Nacional de Pediatría, CIIDIR-IPN, México D.F.
Gac Med Mex. 2001 May-Jun;137(3):227-36.
Therapeutic inefficacy and pharmacologic toxicity has frequently been seen in the clinical use of drugs or medicines in individuals under pharmacological treatment. Due to the presence of drug metabolizing enzymes, medicines may participate as substrate inhibitors or enzyme inductors. Their activity may vary among individuals. This enzymatic variability may be assessed through the analysis of recombinant DNA, using restriction analysis of the genomic DNA (fragment restriction of polymorphic length) and the enzymatic amplification of DNA through PCR (polymerase chain reaction). This technology has been used in clinical studies which allow us to know the mechanisms of inherited variations in response to drugs regulated by each individual's genes dependent on different races. These enzymatic differences may also be influenced by nutritional habits or environmental factors. This study deals with the importance of understanding the metabolism of drugs applied to the therapeutic management of individuals with therapeutic inefficacy or pharmacologic toxicity.
在接受药物治疗的个体中，药物治疗无效和药物毒性在临床用药时屡见不鲜。由于存在药物代谢酶，药物可能作为底物抑制剂或酶诱导剂参与其中。它们的活性在个体间可能存在差异。这种酶的变异性可通过重组DNA分析、利用基因组DNA的限制性分析（多态性长度片段限制性分析）以及通过聚合酶链反应（PCR）对DNA进行酶促扩增来评估。这项技术已用于临床研究，使我们能够了解不同种族个体基因调控的药物反应中遗传变异的机制。这些酶的差异也可能受到饮食习惯或环境因素的影响。本研究探讨了理解药物代谢对于治疗无效或药物毒性个体的治疗管理的重要性。
